Omeros/$OMER
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Omeros
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Ticker
$OMER
Sector
Primary listing
Employees
175
Headquarters
Website
Omeros Metrics
BasicAdvanced
$1.1bn
-
-$0.05
2.53
-
Price and volume
Market cap
$1.1bn
Beta
2.53
52-week high
$17.65
52-week low
$2.95
Average daily volume
1.2m
Financial strength
Current ratio
2.763
Quick ratio
2.341
Long term debt to equity
-169.864
Total debt to equity
-206.084
Interest coverage (TTM)
-9.23%
Profitability
EBITDA (TTM)
-121.832
Effective tax rate (TTM)
-71.96%
Management effectiveness
Return on assets (TTM)
-25.47%
Return on equity (TTM)
3.16%
Valuation
Price to book
-8.63
Price to tangible book (TTM)
-8.63
Price to free cash flow (TTM)
7.487
Free cash flow yield (TTM)
13.36%
Free cash flow per share (TTM)
1.95
Growth
Earnings per share change (TTM)
-98.04%
3-year earnings per share growth (CAGR)
-58.83%
10-year earnings per share growth (CAGR)
-30.48%
What the Analysts think about Omeros
Analyst ratings (Buy, Hold, Sell) for Omeros stock.
Omeros Financial Performance
Revenues and expenses
Omeros Earnings Performance
Company profitability
Omeros News
AllArticlesVideos
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)
Business Wire·2 weeks ago
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
Business Wire·1 month ago
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Omeros stock?
Omeros (OMER) has a market cap of $1.1B as of May 01, 2026.
What is the P/E ratio for Omeros stock?
The price to earnings (P/E) ratio for Omeros (OMER) stock is 0 as of May 01, 2026.
Does Omeros stock pay dividends?
No, Omeros (OMER) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next Omeros dividend payment date?
Omeros (OMER) stock does not pay dividends to its shareholders.
What is the beta indicator for Omeros?
Omeros (OMER) has a beta rating of 2.53. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.